Ramelteon and Next-Day Drowsiness

Evidence on Next-Day Effects

The American Academy of Sleep Medicine found that ramelteon generally does not cause significant next-day drowsiness, with only isolated and inconsistent evidence of mild next-day effects that typically resolve with continued use 1, 2, 3
Three clinical studies specifically assessed next-day impairment associated with ramelteon, with the majority showing no significant residual effects compared to placebo 1, 2, 3
Roth and colleagues found no significant residual effects on digit-symbol substitution test (DSST), immediate and delayed recall, subjective alertness, or concentration in older adults 2, 3
Zammitt et al. reported only isolated, transient impairments in immediate recall, delayed recall, alertness, and concentration 2, 3
Mayer found no consistent evidence of next-day impairment in alertness, recall, DSST, or visual analog scales of mood, energy, or cognition 2, 3

Unlike benzodiazepines and non-benzodiazepine hypnotics, ramelteon has not been associated with significant next-day cognitive or motor impairment 4
Ramelteon has no abuse potential and is not classified as a controlled substance, making it a suitable option for patients with a history of substance use disorders 4

The American Academy of Sleep Medicine suggests ramelteon as a treatment option for sleep onset insomnia with a weak recommendation, noting its relatively benign side effect profile 1, 2, 3
The efficacy of ramelteon for reducing sleep latency is modest (mean decrease of 9.57 minutes) compared to placebo 1, 2, 5
In elderly patients, ramelteon may be preferable to other hypnotics due to its minimal next-day effects and low risk of falls or cognitive impairment 6

The FDA specifically warns about daytime impairment with suvorexant, highlighting a critical safety distinction between suvorexant and ramelteon 7
The American College of Physicians guideline emphasizes the need to discuss harms including next-day effects when considering suvorexant, underscoring the importance of patient counseling 7

Ramelteon reduces sleep latency by approximately 9.57 minutes compared to placebo, with modest efficacy for sleep onset difficulties 8
The American Academy of Sleep Medicine gives ramelteon a WEAK recommendation due to marginal efficacy, though benefits outweigh minimal harms 8
The American Academy of Sleep Medicine notes that ramelteon works best for sleep onset difficulties rather than sleep maintenance, guiding its appropriate use 9
Suvorexant has moderate-quality evidence for improving sleep outcomes and treatment response, but with a higher risk of next-day impairment and abnormal sleep behaviors 7